Shampa Das

Professor Shampa Das serves as Professor of Antimicrobial Therapeutics and Deputy Head of the Department of Pharmacology and Therapeutics at the University of Liverpool. An experienced Clinical Pharmacology Scientist with 17 years in the pharmaceutical industry, she specializes in leveraging pharmacokinetics/pharmacodynamics (PK/PD) to develop clinical pharmacology strategies and dose regimens for antimicrobial agents, contributing to regulatory approvals in Europe and the US for antibiotics including Zavicefta and Zinforo.

Her academic foundation includes a BSc in Biochemistry and Physiology (1995) and PhD (1999) from the University of Sheffield, followed by post-doctoral research at the University of Manchester.

Das's research program centers on antimicrobial drug development, with core expertise in designing PK/PD packages for dose selection, developing paediatric dosing strategies, and optimizing regimens for special populations. She focuses on translating preclinical PK/PD data to clinical practice through innovative modeling approaches that bridge data gaps for regulatory submissions.

Analysis of her 2024-2025 publications reveals consistent emphasis on PK/PD modeling of antibiotics against multidrug-resistant pathogens, including meropenem for Pseudomonas aeruginosa pneumonia, aztreonam-avibactam dosing in renal impairment, and novel compounds like BWC0977. These works address critical therapeutic gaps in neonatal sepsis and complicated infections using advanced in vitro and in vivo models.

Her leadership is recognized through key appointments: serving on the EUCAST steering committee for breakpoint decisions, co-chairing the ESCMID-ASM Joint Conference committee on AMR drug development, and advising CARB-X and GARDP initiatives, though no specific scientific awards are detailed in the provided text.

Professor Das actively mentors students through thesis supervision and teaches core pharmacology modules including Cancer Clinical Trials and Pharmacology Research Projects. Her research program is robustly funded by international grants from the Fleming Fund, GARDP, FDA, and European Commission supporting projects on antimicrobial combinations for neonatal sepsis and novel antibiotic development across global settings.

She leads the Antimicrobial Pharmacodynamics and Therapeutics group at the University of Liverpool, collaborating with biotech and pharma companies to develop new antimicrobial agents through PK/PD-driven dose optimization strategies.